Curated News
By: NewsRamp Editorial Staff
October 28, 2026

HeartBeam to Present ALIGN-ACS Pilot Study Results at TCT 2026

Discuss on Substack
Original Source

TLDR

  • HeartBeam's 3D ECG could disrupt standard 12-lead ECG by offering portable, cable-free heart attack assessment and capturing market share.
  • The ALIGN-ACS pilot enrolled 132 chest pain patients to compare HeartBeam's credit card-sized 3-lead device with standard 12-lead ECG for acute coronary syndrome detection.
  • HeartBeam's portable 3D ECG aims to enable faster heart attack assessment outside hospitals, potentially saving lives through earlier cardiac care.
  • HeartBeam's credit card-sized device synthesizes 3D ECG signals into a 12-lead ECG and holds over 20 patents for cardiac monitoring innovation.

Impact - Why it Matters

The presentation of HeartBeam's ALIGN-ACS pilot study results at TCT 2026 is a critical milestone for the company and for cardiac care. If the 3D ECG technology demonstrates comparable accuracy to standard 12-lead ECGs in detecting acute coronary syndrome, it could enable faster, more accessible heart attack assessment outside of traditional hospital settings. This would be particularly impactful for emergency departments and remote or resource-limited environments, where quick triage is essential. For investors, positive data could accelerate the path to a U.S. pivotal study and eventual FDA clearance, potentially unlocking a large market opportunity. For patients, the technology promises to deliver actionable heart intelligence anytime, anywhere, transforming how cardiac conditions are detected and managed.

Summary

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care, has announced that results from its ALIGN-ACS pilot study will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 conference in San Diego. The study evaluated HeartBeam's 3D electrocardiogram (ECG) technology for heart attack assessment. The presentation is scheduled for Nov. 1 at 1:20 p.m. Pacific time and will be delivered by Dr. Graham Nichol of the University of Washington. The pilot study enrolled 132 emergency department patients presenting with chest pain at two clinical sites in Belgrade, Serbia, and compared the HeartBeam System—a credit card-sized, three-lead device—with a standard 12-lead ECG for detecting acute coronary syndrome.

HeartBeam founder and President Branislav Vajdic said the study represents an important step in evaluating the company's technology against conventional ECG systems in patients with suspected heart attacks. The technology has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation and has been accepted into the agency's Total Product Life Cycle Advisory Program. HeartBeam expects the pilot study findings to help guide the design of a U.S. pivotal study anticipated to begin in the first quarter of 2027. Members of the management team will also be available for meetings during the conference. To view the full press release, visit https://ibn.fm/IA88r.

HeartBeam, Inc. (NASDAQ: BEAT) is dedicated to transforming the detection and monitoring of critical cardiac conditions. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility, redefining the future of cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam to Present ALIGN-ACS Pilot Study Results at TCT 2026

Blockchain registration record for this content